CA2377937A1 - Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1) - Google Patents

Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1) Download PDF

Info

Publication number
CA2377937A1
CA2377937A1 CA002377937A CA2377937A CA2377937A1 CA 2377937 A1 CA2377937 A1 CA 2377937A1 CA 002377937 A CA002377937 A CA 002377937A CA 2377937 A CA2377937 A CA 2377937A CA 2377937 A1 CA2377937 A1 CA 2377937A1
Authority
CA
Canada
Prior art keywords
rats
oligonucleotide
mglur1
treated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377937A
Other languages
English (en)
French (fr)
Inventor
Marian E. Fundytus
Terence J. Coderre
S. Robin Cohen
James L. Henry
Anneli Vainio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2377937A1 publication Critical patent/CA2377937A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002377937A 1999-07-15 2000-07-17 Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1) Abandoned CA2377937A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14400499P 1999-07-15 1999-07-15
US60/144,004 1999-07-15
PCT/CA2000/000824 WO2001005963A2 (en) 1999-07-15 2000-07-17 ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1)

Publications (1)

Publication Number Publication Date
CA2377937A1 true CA2377937A1 (en) 2001-01-25

Family

ID=22506645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377937A Abandoned CA2377937A1 (en) 1999-07-15 2000-07-17 Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1)

Country Status (4)

Country Link
EP (1) EP1238069A2 (de)
AU (1) AU5959900A (de)
CA (1) CA2377937A1 (de)
WO (1) WO2001005963A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309570B2 (en) * 2001-06-07 2012-11-13 Analgesic Neuropharmaceuticals, Llc Treatment of central neuropathic pain
WO2005075987A2 (en) * 2004-01-28 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 1 (mglur1)
AU2005327517B2 (en) * 2004-06-30 2011-05-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
EP2578216A1 (de) 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Verfahren zur Behandlung von Fragilem-X-Syndrom
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Also Published As

Publication number Publication date
AU5959900A (en) 2001-02-05
WO2001005963A3 (en) 2001-11-08
EP1238069A2 (de) 2002-09-11
WO2001005963A2 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
US11530410B2 (en) Methods for treating hypercholesterolemia
AU2017202862B2 (en) Modulation of factor 11 expression
JP6704439B2 (ja) ハンチンチン発現の修飾
JP6934895B2 (ja) アポリポタンパク質（ａ）発現を調節するための方法および組成物
AU2008323970B2 (en) Modulation of Factor 7 expression
JP6538736B2 (ja) Ｇｃｇｒ発現のアンチセンス調整
JP3054745B2 (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
US20030186920A1 (en) Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
WO2003056010A2 (en) An antisense strategy to modulate estrogen receptor response (er. alpha. and/or er. beta.)
JP2013504329A5 (de)
KR20150003824A (ko) 당뇨병 치료 및/또는 이식 후 췌장섬 생존 촉진 방법
KR20210008498A (ko) Fxi 발현을 감소시키기 위한 화합물 및 방법
CA2377937A1 (en) Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1)
WO2003057843A2 (en) Methods and materials for modulating trpc4
US20130028889A1 (en) Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2004093778A2 (en) Oligonucleotides that block toll-like receptors
US20080119423A1 (en) Methods and Materials For Modulating p2x2
US20060246432A1 (en) Methods and materials for modulating task-3

Legal Events

Date Code Title Description
FZDE Discontinued